Apoptosis in the anucleate platelet

Blood Reviews

Volumn 26, Issue 2, 2012, Pages 51-63

  Leytin, Valery ^a,b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Toronto Platelet Immunobiology Group   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apoptosis triggers and markers; Cyclosporin A; Eptifibatide (Integrilin); Extrinsic and intrinsic apoptosis pathways; Intravenous immunoglobulin; Mitochodrial control; PAR 1, GPIIbIIIa, GPIb receptors; Platelet apoptosis; Shear stress; Tirofiban (Aggrastat)

Indexed keywords

ABCIXIMAB; APOPTOSIS INDUCING FACTOR; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 10; CASPASE 8; CYCLOSPORIN A; CYTOCHROME C; DEATH RECEPTOR 3; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DECOY RECEPTOR 3; EPTIFIBATIDE; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FLICE INHIBITORY PROTEIN; GLYCOPROTEIN IB ALPHA; IMMUNOGLOBULIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; ORBOFIBAN; PROTEIN BCL 2; PROTEINASE ACTIVATED RECEPTOR 1; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TIROFIBAN; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ANUCLEATE THROMBOCYTE; APOPTOSIS; ARTICLE; CELL AGING; CELL NUCLEUS; CELL TYPE; ENZYME ACTIVATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHEAR STRESS; STIMULUS RESPONSE; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE LIFESPAN; THROMBOCYTE PRESERVATION;

APOPTOSIS; BLOOD PLATELETS; HUMANS; MICROSCOPY, ELECTRON, SCANNING; MITOCHONDRIA; PLATELET MEMBRANE GLYCOPROTEINS;

EID: 84856527134     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2011.10.002     Document Type: Article

References (168)

1. Smyth S.S., McEver R.P., Weyrich A.S., Morrell C.N., Hoffman M.R., Arepally G.M., et al. Platelet functions beyond hemostasis. J Thromb Haemost 2009, 7:1759-1766.
2. Semple J.W., Italiano J.E., Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011, 11:264-274.
3. Warshaw A.L., Laster L., Shulman N.R. The stimulation by thrombin of glucose oxidation in human platelets. J Clin Invest 1966, 45:1923-1934.
4. Warshaw A.L., Laster L., Shulman N.R. Protein synthesis by human platelets. J Biol Chem 1967, 242:2094-2097.
5. Booyse F., Rafelson M.E. In vitro incorporation of amino-acids into the contractile protein of human blood platelets. Nature 1967, 215:283-284.
6. Booyse F.M., Rafelson M.E. Stable messenger RNA in the synthesis of contractile protein in human platelets. Biochim Biophys Acta 1967, 145:188-190.
7. Weyrich A.S., Dixon D.A., Pabla R., Elstad M.R., McIntyre T.M., Prescott S.M., et al. Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc Natl Acad Sci U S A 1998, 95:5556-5561.
8. Pabla R., Weyrich A.S., Dixon D.A., Bray P.F., McIntyre T.M., Prescott S.M., et al. Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets. J Cell Biol 1999, 144:175-184.
9. Lindemann S., Tolley N.D., Dixon D.A., McIntyre T.M., Prescott S.M., Zimmerman G.A., et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001, 154:485-490.
10. Weyrich A.S., Denis M.M., Schwertz H., Tolley N.D., Foulks J., Spencer E., et al. mTORdependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets. Blood 2007, 109:1975-1983.
11. Weyrich A.S., Lindemann S., Tolley N.D., Kraiss L.W., Dixon D.A., Mahoney T.M., et al. Change in protein phenotype without a nucleus: translational control in platelets. Semin Thromb Hemost 2004, 30:491-498.
12. Lindemann S., Gawaz M. The active platelet: translation and protein synthesis in an anucleate cell. Semin Thromb Hemost 2007, 33:144-150.
13. Zimmerman G.A., Weyrich A.S. Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function. Arterioscler Thromb Vasc Biol 2008, 28:s17-s24.
14. Weyrich A.S., Schwertz H., Kraiss L.W., Zimmerman G.A. Protein synthesis by platelets: historical and new perspectives. J Thromb Haemost 2008, 7:241-246.
15. Schubert P., Devine D.V. De novo protein synthesis in mature platelets: a consideration for transfusion medicine. Vox Sang 2010, 99:112-122.
16. Kieffer N., Guichard J., Farcet J.P., Vainchenker W., Breton-Gorius J. Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem 1987, 164:189-195.
17. Panes O., Matus V., Saez C.G., Quiroga T., Pereira J., Mezzano D. Human platelets synthesize and express functional tissue factor. Blood 2007, 109:5242-5250.
18. Mezzano D., Matus V., Saez C.G., Pereira J., Panes O. Tissue factor storage, synthesis and function in normal and activated human platelets. Thromb Res 2008, 122(Suppl. 1):S31-S36.
19. Vanags D.M., Orrenius S., Aguilar-Santelises M. Alterations in Bcl-2/Bax protein levels in platelets form part of an ionomycin-induced process that resembles apoptosis. Br J Haematol 1997, 99:824-831.
20. Li J., Xia Y., Bertino A.M., Coburn J.P., Kuter D.J. The mechanism of apoptosis in human platelets during storage. Transfusion 2000, 40:1320-1329.
21. Brown S.B., Clarke M.C.H., Magowan L., Sanderson H., Savill J. Constitutive death of platelets leading to scavenger receptor-mediated phagocytosis. A caspase-independent cell clearance program. J Biol Chem 2000, 275:5987-5996.
22. Kuter D.J. Apoptosis in platelets during ex vivo storage. Vox Sang 2002, 83(Suppl. 1):311-313.
23. Leytin V., Allen D.J., Mykhaylov S., Lyubimov E., Freedman J. Thrombin-triggered platelet apoptosis. J Thromb Haemost 2006, 4:2656-2663.
24. Lopez J.J., Salido G.M., Pariente J.A., Rosado J.A. Thrombin induces activation and translocation of Bid, Bax and Bak to the mitochondria in human platelets. J Thromb Haemost 2008, 6:1780-1788.
25. Kerr J.F.R., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26:239-257.
26. Schulze-Osthoff K., Walczak H., Drodge W., Krammer P.H. Cell nucleus and DNA fragmentation are not required for apoptosis. J Cell Biol 1994, 127:15-20.
27. Jacobson M.D., Burne J.F., Raff M.C. Programmed cell death and Bcl-2 protection in the absence of a nucleus. EMBO J 1994, 13:1899-1910.
28. Martin S.J., Finucane D.M., Amarante-Mendes G.P., O'Brien G.A., Green D.R. Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity. J Biol Chem 1996, 271:28753-28756.
29. Castedo M., Hirsch T., Susin A.S., Zamzami N., Marchetti P., Macho A., et al. Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis. J Immunol 1996, 157:512-521.
30. Dachary-Prigent J., Freyssinet J.M., Pasquet J.M., Carron J.C., Nurden A.T. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups. Blood 1993, 81:2554-2565.
31. Shcherbina A., Remold-O'Donnell E. Role of caspase in a subset of human platelet activation responses. Blood 1999, 93:4222-4231.
32. Wolf B.B., Goldstein J.C., Stennicke H.R., Beere H., Amarante-Mendes G.P., Salvesen G.S., et al. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. Blood 1999, 94:1683-1692.
33. Keuren J.F., Wielders S.J., Ulrichts H., Hackeng T., Heemskerk J.W., Deckmyn H., et al. Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1. Arterioscler Thromb Vasc Biol 2005, 25:1499-1505.
34. Ben Amor N., Pariente J.A., Salido G.M., Bartegi A., Rosado J.A. Caspases 3 and 9 are translocated to the cytoskeleton and activated by thrombin in human platelets. Evidence for the involvement of PKC and the actin filament polymerization. Cell Signal 2006, 18:1252-1261.
35. Amor N.B., Pariente J.A., Salido G.M., Rosado J.A., Bartegi A. Thrombin-induced caspases 3 and 9 translocation to the cytoskeleton is independent of changes in cytosolic calcium in human platelets. Blood Cells Mol Dis 2006, 36:392-401.
36. Leytin V., Allen D.J., Lyubimov E., Freedman J. Higher thrombin concentrations are required to induce platelet apoptosis than to induce platelet activation. Br J Haematol 2007, 136:762-764.
37. Lopez J.J., Salido G.M., Gomez-Arteta E., Rosado J.A., Pariente J.A. Thrombin induces apoptotic events through the generation of reactive oxygen species in human platelets. J Thromb Haemost 2007, 5:1283-1291.
38. Leung R., Gwozdz A.M., Wang H., Bang K.W.A., Packham M.A., Freedman J., et al. Persistence of procoagulant surface expression on activated human platelets: involvement of apoptosis and aminophospholipid translocase activity. J Thromb Haemost 2007, 5:560-570.
39. Leytin V., Mutlu A., Mykhaylov S., Allen D.J., Gyulkhandanyan A.G., Freedman J. The GPIIbIIIa antagonist drugs eptifibatide and tirofiban do not induce activation of apoptosis executioner caspase-3 in resting human platelets but inhibit caspase-3 activation in platelets stimulated with thrombin or calcium ionophore A23187. Haematologica 2009, 94:1783-1784.
40. Lin K.H., Chang H.C., Lu W.J., Jayakumar T., Chou H.C., Fong T.H., et al. Comparison of the relative activities of inducing platelet apoptosis stimulated by various platelet-activating agents. Platelets 2009, 20:575-581.
41. Gwozdz A.M., Leung R., Wang H., Bang K.W., Packham M.A., Freedman J., et al. Calpain inhibition by calpeptin does not prevent APLT activity reduction in PS-exposing platelets, but calpeptin has independent pro-apoptotic effects. Thromb Haemost 2010, 103:1218-1227.
42. Tonon G., Luo X., Greco N.J., Chen W., Shi Y., Jamieson G.A. Weak platelet agonists and U46619 induce apoptosis-like events in platelets, in the absence of phosphatidylserine exposure. Thromb Res 2002, 107:345-350.
43. Remenyi G., Szasz R., Friese P., Dale G.L. Role of mitochondrial permeability transition pore in coated-platelet formation. Arterioscler Thromb Vasc Biol 2005, 25:467-471.
44. Dale G.L., Friese P. Bax activators potentiate coated-platelet formation. J Thromb Haemost 2006, 4:2664-2669.
45. Jobe S.M., Wilson K.M., Leo L., Raimondi A., Molkentin J.D., Lentz S.R., et al. Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. Blood 2008, 111:1257-1265.
46. Perrotta P.L., Perrotta C.L., Snyder E.L. Apoptotic activity in stored human platelets. Transfusion 2003, 43:526-535.
47. Leytin V., Freedman J. Platelet apoptosis in stored platelet concentrates and other models. Transfus Apher Sci 2003, 28:285-295.
48. Leytin V., Allen D.J., Mykhaylov S., Mis L., Lyubimov E.V., Garvey B., et al. Pathologic high shear stress induces apoptosis events in human platelets. Biochem Biophys Res Commun 2004, 320:303-310.
49. Leytin V., Allen D.J., Mutlu A., Gyulkhandanyan A.V., Mykhaylov S., Freedman J. Mitochondrial control of platelet apoptosis: effect of cyclosporin A, an inhibitor of the mitochondrial permeability transition pore. Lab Invest 2009, 89:374-384.
50. Rand M.L., Wang H., Bang K.W.A., Poon K.S.V., Packham M.A., Freedman J. Procoagulant surface exposure and apoptosis in rabbit platelets: association with shortened survival and steady-state senescence. J Thromb Haemost 2004, 2:651-659.
51. Pereira J., Soto M., Palomo I., Ocqueteau M., Coetzee L.M., Astudillo S., et al. Platelet aging in vivo is associated with activation of apoptotic pathways: studies in a model of suppressed thrombopoiesis in dogs. Thromb Haemost 2002, 87:905-909.
52. Clarke M.C., Savill J., Jones D.B., Noble B.S., Brown S.B. Compartmentalized megakaryocyte death generates functional platelets committed to caspase-independent death. J Cell Biol 2003, 160:577-587.
53. Bergmeier W., Burger P.C., Piffath C.L., Hoffmeister K.M., Hartwig J.H., Nieswandt B., et al. Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. Blood 2003, 102:4229-4235.
54. Leytin V., Mykhaylov S., Starkey A.F., Allen D.J., Lau H., Ni H., et al. Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia. Br J Haematol 2006, 133:78-82.
55. Piguet P.F., Vesin C. Modulation of platelet caspases and life-span by anti-platelet antibodies in mice. Eur J Haematol 2002, 68:253-261.
56. Li S., Wang Z., Liao Y., Zhang W., Shi Q., Yan R., et al. The glycoprotein Ibα-von Willebrand factor interaction induces platelet apoptosis. J Thromb Haemost 2010, 8:341-350.
57. Mason K.D., Carpinelli M.R., Fletcher J.I., Collinge J.E., Hilton A.A., Ellis S., et al. Programmed anuclear cell death delimits platelet life span. Cell 2007, 128:1173-1186.
58. Zhang H., Nimmer P.M., Tahir S.K., Chen J., Fryer R.M., Hahn K.R., et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007, 14:943-951.
59. Dasgupta S.K., Argaiz E.R., Mercado J.E., Maul H.O., Garza J., Enriquez A.B., et al. Platelet senescence and phosphatidylserine exposure. Transfusion 2010, 50:2167-2175.
60. Kodama T., Takehara T., Hikita H., Shimizu S., Shigekawa M., Li W., et al. BH3-only activator proteins, Bid and Bim, are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by Bcl-xL deficiency: Molecular requisites for the mitochondrial pathway to apoptosis in platelets. J Biol Chem 2011, 286:13905-13913.
61. Lopez J.J., Redondo P.C., Salido G.M., Pariente J.A., Rosado J.A. N, N, N'N'-tetrakis(2-pyridylmethyl)ethylenediamine induced apoptosis through the activation of caspase-3 and -8 in human platelets. A role for endoplasmic reticulum stress. J Thromb Haemost 2009, 7:992-999.
62. Lin K.H., Hsiao G., Shih C.M., Chou D.S., Sheu J.R. Mechanisms of resveratrol-induced platelet apoptosis. Cardiovasc Res 2009, 83:575-585.
63. Augereau O., Rossignol R., DeGiorgi F., Mazat J.P., Letellier T., Dachary-Prigent J. Apoptotic-like mitochondrial events associated to phosphatidylserine exposure in blood platelets induced by local anaesthetics. Thromb Haemost 2004, 92:104-113.
64. Wang Z., Li S., Shi Q., Yan R., Liu G., Dai K. Calmodulin antagonists induce platelet apoptosis. Thromb Res Apr 2010, 125:340-350.
65. Kuter D.J. Platelet storage: the role of apoptosis in transfusion medicine and the development of the platelet storage lesion. The Compendium of AABB 53rd Annual Meeting 2000, 383-388. [Washington].
66. Snyder E.L., Kuter D.J. Apoptosis in transfusion medicine: of death and dying - is that all there is?. Transfusion 2000, 40:135-138.
67. Plenchette S., Moutet M., Benguella M., N'Gondara J.P., Guigner F., Coffe C., et al. Early increase in DcR2 expression and late activation of caspases in the platelet storage lesion. Leukemia 2001, 15:1572-1581.
68. Bertino A.M., Qi X.Q., Li J., Xia Y., Kuter D.J. Apoptotic markers are increased in platelets stored at 37 degrees C. Transfusion 2003, 43:857-866.
69. Wadhawan V., Karim Z.A., Mukhopadhyay S., Gupta R., Dikshit M., Dash D. Platelet storage under in vitro condition is associated with calcium-dependent apoptosis-like lesions and novel reorganization in platelet cytoskeleton. Arch Biochem Biophys 2004, 422:183-190.
70. Liu Q., Xu L., Jiao S.X., Wang T.X., Song Y., Wen Z.K. Trehalose inhibited the phagocytosis of refrigerated platelets in vitro via preventing apoptosis. Transfusion 2009, 49:2158-2166.
71. Albanyan A.M., Harrison P., Murphy M.F. Markers of platelet activation and apoptosis during storage of apheresis- and buffy coat-derived platelet concentrates for 7 days. Transfusion 2009, 49:108-117.
72. Leytin V., Allen D.J., Mutlu A., Mykhaylov S., Lyubimov E., Freedman J. Stored platelet concentrates produced by the platelet-rich plasma method are more resistant to apoptosis but more sensitive to activation than are platelets prepared by the buffy-coat and apheresis methods. Transfusion 2009, 49:1493-1494.
73. Cookson P., Sutherland J., Turner C., Bashir S., Wiltshire M., Hancock V., et al. Platelet apoptosis and activation in platelet concentrates stored for up to 12 days in plasma or additive solution. Transfus Med 2010, 20:392-402.
74. Bozza F.A., Weyrich A.S. Mitochondria push platelets past their prime. Blood 2008, 111:1257-1258.
75. Kile B.T. The role of the intrinsic apoptosis pathway in platelet life and death. J Thromb Haemost 2009, 7(Suppl. 1):214-217.
76. White M.J., Kile B.T. Apoptotic processes in megakaryocytes and platelets. Semin Hematol 2010, 47:227-234.
77. Piguet P.F., Kan C.D., Vesin C. Thrombocytopenia in an animal model of malaria is associated with an increased caspase-mediated death of thrombocytes. Apoptosis 2002, 7:91-98.
78. Piguet P.F., Vesin C., Kan C.D. Activation of platelet caspases by TNF and its consequences for kinetics. Cytokine 2002, 18:222-230.
79. Rand M.L., Wang H., Bang K.W.A., Packham M.A., Freedman J. Rapid clearance of procoagulant platelet-derived microparticles from the circulation of rabbits. J Thromb Haemost 2006, 4:1621-1623.
80. Rand M.L., Wang H., Bang K.W., Packham M.A., Freedman J. Persistence of phosphatidylserine exposure on activated platelets in vivo in rabbits. Thromb Haemost 2007, 98:477-478.
81. Dowling M.R., Josefsson E.C., Henley K.J., Hodgkin P.D., Kile B.T. Platelet senescence is regulated by an internal timer, not damage inflicted by hits. Blood 2010, 116:1776-1778.
82. Kelly P.N., White M.J., Goschnick M.W., Fairfax K.A., Tarlinton D.M., Kinkel S.A., et al. Individual and overlapping roles of BH3-only proteins Bim and Bad in apoptosis of lymphocytes and platelets and in suppression of thymic lymphoma development. Cell Death Differ 2010, 17:1655-1664.
83. Bonomini M., Dottori S., Amoroso L., Arduini A., Sirolli V. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia. J Thromb Haemost 2004, 2:1275-1281.
84. Yeh J.J., Tsai S., Wu D.C., Wu J.Y., Liu T.C., Chen A. P-selectin-dependent platelet aggregation and apoptosis may explain the decrease in platelet count during Helicobacter pylori infection. Blood 2010, 115:4247-4253.
85. Rand M.L., Wang H., Bang K.W., Teitel J.M., Blanchette V.S., Freedman J., et al. Phosphatidylserine exposure and other apoptotic-like events in Bernard-Soulier syndrome platelets. Am J Hematol 2010, 85:584-592.
86. Catani L., Fagioli M.E., Tazzari P.L., Ricci F., Curti A., Rovito M., et al. Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol 2006, 34:879-887.
87. Speer O., Schmugge M., Azzouzi I., Rand M.L., Kroiss S. Apoptosis in platelets from pediatric patients with acute immune thrombocytopenic purpura (ITP) is ameliorated by IVIg. Blood 2008, 112:1172a.
88. Cohen Z., Gonzales R.F., Davis-Gorman G., McDonagh P.F. Thrombin activity and platelet microparticle formation are increased in type 2 diabetic platelets: a potential correlation with caspase activation. Thromb Res 2002, 107:217-221.
89. Arachiche A., Kerbiriou-Nabias D., Garcin I., Letellier T., Dachary-Prigent J. Rapid procoagulant phosphatidylserine exposure relies on high cytosolic calcium rather than on mitochondrial depolarization. Arterioscler Thromb Vasc Biol 2009, 29:1883-1889.
90. Schoenwaelder S.M., Yuan Y., Josefsson E.C., White M.J., Yao Y., Mason K.D., et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009, 114:663-666.
91. Leytin V., Allen D.J., Mutlu A., Mykhaylov S., Lyubimov E., Freedman J. Platelet activation and apoptosis are different phenomena: evidence from the sequential dynamics and the magnitude of responses during platelet storage. Br J Haematol 2008, 142:494-497.
92. Verhoeven A.J., Verhaar R., Gouwerok E.G., de Korte D. The mitochondrial membrane potential in human platelets: a sensitive parameter for platelet quality. Transfusion 2005, 45:82-89.
93. Schwertz H., Köster S., Kahr W.H., Michetti N., Kraemer B.F., Weitz D.A., et al. Anucleate platelets generate progeny. Blood 2010, 115:3801-3809.
94. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science 1998, 281:1305-1308.
95. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
96. Thornberry N.A., Lazebnic Y. Caspases: enemies within. Science 1998, 281:1312-1316.
97. Budihardjo I., Oliver H., Lutter M., Luo X., Wang X. Biochemical pathways of caspases: activation during apoptosis. Annu Rev Cell Dev Biol 1999, 15:269-290.
98. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002, 2:420-430.
99. Walczak H., Sprick M.R. Biochemistry and function of the DISC. Trends Biochem Sci 2001, 26:452-453.
100. Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
101. Green D.R., Kroemer G. Pharmacological manipulation of cell death: clinical applications in sight?. J Clin Invest 2005, 115:2610-2617.
102. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007, 87:99-163.
103. Hotchkiss R.S., Strasser A., McDunn J.E., Swanson P.E. Cell death. N Engl J Med 2009, 361:1570-1583.
104. Green D.R., Reed J.C. Mitochondria and apoptosis. Science 1998, 281:1309-1312.
105. Kroemer G., Reed J.C. Mitochondrial control of cell death. Nat Med 2000, 6:513-519.
106. Green D.R., Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004, 305:626-629.
107. Coughlin S.R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005, 3:1800-1814.
108. Lundblad R.L., White G.C. The interaction of thrombin with blood platelets. Platelets 2005, 16:373-385.
109. Bahou W.F. Thrombin receptors. Platelets 2007, 179-200. Academic Press, Amsterdam. A.D. Michelson (Ed.).
110. Hockin M.F., Jones K.C., Everse S.J., Mann K.G. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002, 277:18322-18333.
111. Mann K.G., Brummel K., Butenas S. What is all that thrombin for?. J Thromb Haemost 2003, 1:1504-1514.
112. Bouchard B.A., Butenas S., Mann K.G., Tracy P.B. Interactions between platelets and the coagulation system. Platelets 2007, 377-402. Academic Press, Amsterdam. A.D. Michelson (Ed.).
113. Zong W.-X., Lindsten T., Ross A.J., MacGregor G.R., Thompson C.B. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 2001, 15:1481-1486.
114. Adams J.M., Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 2001, 26:61-66.
115. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol 2005, 5:189-200.
116. Zain J., Huang Y.Q., Feng X., Nierodzik M.L., Li J.J., Karpatkin S. Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. Blood 2000, 95:3133-3138.
117. Flynn A.N., Buret A.G. Proteinase-activated receptor 1 (PAR-1) and cell apoptosis. Apoptosis 2004, 9:729-737.
118. Rosado J.A., Redondo P.C., Salido G.M., Gomez-Arteta E., Sage S.O., Pariente J.A. Hydrogen peroxide generation induces pp 60src activation in human platelets: evidence for the involvement of this pathway in store-mediated calcium entry. J Biol Chem 2004, 279:1665-1675.
119. ι protects human leukemia cells against drug-induced apoptosis. J Biol Chem 1997, 272:27521-27524.
120. Lu Z., Hornia A., Jiang Y.W., Zang Q., Ohno S., Foster D.A. Tumor promotion by depleting cells of protein kinase Cδ. Mol Cell Biol 1997, 17:3418-3428.
121. ι activity is necessary for Bcr-Abl-mediated resistance to drug-induced apoptosis. J Biol Chem 1999, 274:3927-3930.
122. Kothakota S., Azuma T., Reinhard C., Klippel A., Tang J., Chu K., et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 1997, 278:294-298.
123. De Botton S., Sabri S., Daugas E., Zermati Y., Guidotti J.E., Hermine O., et al. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood 2002, 100:1310-1317.
124. Kim S.J., Hwang S.G., Kim I.C., Chun J.S. Actin cytoskeletal architecture regulates nitric oxide-induced apoptosis, dedifferentiation, and cyclooxygenase-2 expression in articular chondrocytes via mitogen-activated protein kinase and protein kinase C pathways. J Biol Chem 2003, 278:42448-42456.
125. Brummel-Ziedins K.E., Pouliot R.L., Mann K.G. Thrombin generation: phenotypic quantitation. J Thromb Haemost 2004, 2:281-288.
126. Walz D.A., Anderson G.F., Ciaglowski R.E., Aiken M., Fenton J.W. Thrombin-elicited contractile responses of aortic smooth muscle. Proc Soc Exp Biol Med 1985, 180:518-526.
127. Plow E.F., Pesho M.M., Ma Y.-Q. Integrin αIIbβ3. Platelets 2007, 165-178. Academic Press, Amsterdam. A.D. Michelson (Ed.).
128. Prévost N., Shattil S.J. Outside-in signaling by integrin αIIbβ3. Platelets 2007, 347-357. Academic Press, Amsterdam. A.D. Michelson (Ed.).
129. Teeling J.L., Jansen-Hendriks T., Kuijpers T.W., de Haas M., van de Winkel J.G., Hack C.E., et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001, 98:1095-1099.
130. Nieswandt B., Bergmeier W., Rackebrandt K., Gessner J.E., Zirngibl H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood 2000, 96:2520-2527.
131. Webster M.L., Sayeh E., Crow M., Chen P., Nieswandt B., Freedman J., et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbα antibodies. Blood 2006, 108:943-946.
132. Webster M.L., Zhu G., Li Y., Ni H. Fc-independent phagocytosis: implications for intravenous IgG therapy in immune thrombocytopenia. Cardiovasc Hematol Disord Drug Targets 2008, 8:278-282.
133. Chen P., Li C., Lang S., Zhu G., Reheman A., Spring C.M., et al. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Blood 2010, 116:3660-3668.
134. Crow A.R., Song S., Semple J.W., Freedman J., Lazarus A.H. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol 2001, 115:679-686.
135. Song S., Crow A.R., Freedman J., Lazarus A.H. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood 2003, 101:3708-3713.
136. Siragam V., Brinc D., Crow A.R., Song S., Freedman J., Lazarus A.H. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?. J Clin Invest 2005, 115:155-160.
137. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486.
138. Lazarus A.H., Crow A.R. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci 2003, 28:249-255.
139. Siragam V., Crow A.R., Brinc D., Song S., Freedman J., Lazarus A.H. Intravenous immunoglobulin ameliorates ITP via activating Fcγ receptors on dendritic cells. Nat Med 2006, 12:688-692.
140. Crow A.R., Lazarus A.H. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-D immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?. Transfus Med Rev 2008, 22:103-116.
141. Ni H., Chen P., Spring C.M., Sayeh E., Semple J.W., Lazarus A.H., et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood 2006, 107:2976-2983.
142. Prasad N.K., Papoff G., Zeuner A., Bonnin E., Kazatchkine M.D., Ruberti G., et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998, 161:3781-3790.
143. Viard I., Wehrli P., Bullani R., Schneider P., Holler N., Salomon D., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998, 282:490-493.
144. Scarborough R.M., Gretler D.D. Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem 2000, 43:3453-3473.
145. Plow E.F., Marguerie G. Inhibition of fibrinogen binding to human platelets by the tetrapeptide glycyl-L-prolyl-L-arginyl-L-proline. Proc Natl Acad Sci U S A 1982, 79:3711-3715.
146. Coller B.S., Peerschke E.I., Scudder L.E., Sullivan C.A. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983, 72:325-338.
147. Topol E.J., Byzova T.V., Plow E.F. Platelet GPIIb-IIIa Blockers. Lancet 1999, 353:227-231.
148. Agah R., Plow E.F., Topol E.J. αIIbβ3 (GPIIbIIIa) antagonists. Platelets 2007, 1145-1163. Academic Press, Amsterdam. A.D. Michelson (Ed.).
149. Jordan R.E., Wagner C.L., Mascelli M.A., Treacy G., Nedelman M.A., Woody J.N., et al. Preclinical development of c7E3 Fab: a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. Adhesion receptors as therapeutic targets 1996, 281-305. CRC Press, Boca Raton, FL. M.A. Horton (Ed.).
150. Coller B.S. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995, 92:2373-2380.
151. Coller B.S. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 1997, 99:11467-11470.
152. Coller B.S. Binding of Abciximab to αvβ3 and activated αMβ2 receptors: with a review of platelet-leukocyte interactions. Thromb Haemost 1999, 82:82326-82336.
153. Buckley C.D., Pilling D., Henriquez N.V., Parsonage G., Threlfall K., Scheel-Toellner D., et al. RGD peptides induce apoptosis by direct caspase-3 activation. Nature 1999, 397:534-539.
154. Adderley S.R., Fitzgerald D.J. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. J Biol Chem 2000, 275:5760-5766.
155. Woods V.L., Wolff L.E., Keller D.M. Resting platelets contain a substantial centrally located pool of glycoprotein IIb-IIIa complex which may be accessible to some but not other extracellular proteins. J Biol Chem 1986, 261:15242-15251.
156. Niiya K., Hodson E., Bader R., Byers-Ward V., Koziol J.A., Plow E.F., et al. Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation. Blood 1987, 70:475-483.
157. Wagner C.L., Mascelli M.A., Neblock D.S., Weisman H.F., Coller B.S., Jordan R.E. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996, 88:9907-9914.
158. van der Wal D.E., Du V.X., Lo K.S., Rasmussen J.T., Verhoef S., Akkerman J.W. Platelet apoptosis by cold-induced glycoprotein Ibα clustering. J Thromb Haemost 2010, 8:2554-2562.
159. Yuan J., Cryns V. Proteases to die for. Genes Dev 1998, 12:1551-1570.
160. Bernardi P., Scorrano L., Colonna R., Petronilli V., Di Lisa F. Mitochondria and cell death. Mechanistic aspects and methodological issues. Eur J Biochem 1999, 264:687-701.
161. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999, 341:233-249.
162. Baines C.P., Kaiser R.A., Purcell N.H., Blair N.S., Osinska H., Hambleton M.A., et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005, 434:658-662.
163. Basso E., Fante L., Fowlkes J., Petronilli V., Forte M.A., Bernardi P. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. J Biol Chem 2005, 280:18558-18561.
164. Leung A.W., Halestrap A.P. Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. Biochim Biophys Acta 2008, 1777:946-952.
165. Nakagawa T., Shimizu S., Watanabe T., Yamaguchi O., Otsu K., Yamagata H., et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005, 434:652-658.
166. Rosado J.A., Lopez J.J., Gomez-Arteta E., Redondo P.C., Salido G.M., Pariente J.A. Early caspase-3 activation independent of apoptosis is required for cellular function. J Cell Physiol 2006, 209:142-152.
167. Brown C.H., Leverett L.B., Lewis C.W., Alfrey C.P., Hellums J.D. Morphological, biochemical and functional changes in human platelets subjected to shear stress. J Lab Clin Med 1975, 86:462-471.
168. Kroll M.H., Hellums J.D., McIntire L.V., Schaffer A.I., Moake J.L. Platelets and shear stress. Blood 1996, 88:1525-1541.